Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2760 Carcinoma, Non-Small-Cell Lung 2260 Prostatic Neoplasms 1425 Colorectal Neoplasms 1290 Neoplasms 1258 Multiple Myeloma 1084 Lung Neoplasms 1048 Neoplasm Metastasis 994 Leukemia, Myeloid, Acute 984 Lymphoma 900 Melanoma 862 Pancreatic Neoplasms 818 Ovarian Neoplasms 805 Carcinoma, Hepatocellular 782 Stomach Neoplasms 753 Recurrence 750 Leukemia 733 Lymphoma, Non-Hodgkin 684 Leukemia, Lymphocytic, Chronic, B-Cell 665 Lymphoma, Large B-Cell, Diffuse 616 Squamous Cell Carcinoma of Head and Neck 615 Precursor Cell Lymphoblastic Leukemia-Lymphoma 605 Head and Neck Neoplasms 596 Brain Neoplasms 592 Carcinoma, Renal Cell 586 Glioblastoma 572 Rectal Neoplasms 563 Myelodysplastic Syndromes 522 Sarcoma 521 Lymphoma, Follicular 516

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡